EA202192800A1 - Способы противоопухолевой терапии - Google Patents

Способы противоопухолевой терапии

Info

Publication number
EA202192800A1
EA202192800A1 EA202192800A EA202192800A EA202192800A1 EA 202192800 A1 EA202192800 A1 EA 202192800A1 EA 202192800 A EA202192800 A EA 202192800A EA 202192800 A EA202192800 A EA 202192800A EA 202192800 A1 EA202192800 A1 EA 202192800A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
antagonist
subject
effective dose
checkpoint inhibitor
Prior art date
Application number
EA202192800A
Other languages
English (en)
Inventor
Тамара Рачмилевиц Минеи
Ицхак Мендел
Нива Яков
Эяль Брайтбарт
Original Assignee
Васкулар Биодженикс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Васкулар Биодженикс Лтд filed Critical Васкулар Биодженикс Лтд
Publication of EA202192800A1 publication Critical patent/EA202192800A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к способам лечения опухоли у нуждающегося в этом субъекта, предусматривающим введение субъекту комбинации эффективной дозы вектора, содержащего ген химерного белка на основе Fas, функционально связанный с промотором, специфическим в отношении эндотелиальных клеток, и эффективной дозы ингибитора контрольной точки иммунного ответа. Согласно некоторым аспектам настоящего раскрытия ингибитор контрольной точки иммунного ответа представляет собой антагонист PD-1 или антагонист PD-L1.
EA202192800A 2019-04-12 2020-04-13 Способы противоопухолевой терапии EA202192800A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833402P 2019-04-12 2019-04-12
PCT/IB2020/053477 WO2020208612A1 (en) 2019-04-12 2020-04-13 Methods of anti-tumor therapy

Publications (1)

Publication Number Publication Date
EA202192800A1 true EA202192800A1 (ru) 2022-03-30

Family

ID=70333996

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192800A EA202192800A1 (ru) 2019-04-12 2020-04-13 Способы противоопухолевой терапии

Country Status (13)

Country Link
US (1) US20220185891A1 (ru)
EP (1) EP3952903A1 (ru)
JP (1) JP2022528425A (ru)
KR (1) KR20210152504A (ru)
CN (1) CN113710265A (ru)
AU (1) AU2020271998A1 (ru)
BR (1) BR112021020225A2 (ru)
CA (1) CA3134080A1 (ru)
EA (1) EA202192800A1 (ru)
IL (1) IL287135A (ru)
MX (1) MX2021012398A (ru)
SG (1) SG11202109441UA (ru)
WO (1) WO2020208612A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245248A1 (en) * 2022-06-22 2023-12-28 Race Oncology Ltd Treatment of melanoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
WO2011083464A2 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
EA022941B1 (ru) 2010-10-18 2016-03-31 Тотал Ресерч Энд Текнолоджи Фелюи Способ увеличения индекса текучести расплава вспениваемого винилароматического полимера
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
NZ707336A (en) * 2012-10-17 2019-01-25 Vascular Biogenics Ltd Treatment methods using adenovirus
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2015197874A2 (en) * 2014-06-27 2015-12-30 Apogenix Gmbh Combination of cd95/cd95l inhibition and cancer immunotherapy
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors

Also Published As

Publication number Publication date
EP3952903A1 (en) 2022-02-16
KR20210152504A (ko) 2021-12-15
WO2020208612A1 (en) 2020-10-15
IL287135A (en) 2021-12-01
MX2021012398A (es) 2021-11-12
BR112021020225A2 (pt) 2021-12-07
JP2022528425A (ja) 2022-06-10
US20220185891A1 (en) 2022-06-16
SG11202109441UA (en) 2021-09-29
AU2020271998A1 (en) 2021-09-30
CA3134080A1 (en) 2020-10-15
CN113710265A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
EA201890113A1 (ru) Композиции и способы ингибирования активности аргиназы
EA201691487A1 (ru) Антитела человека к pd-l1
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201591069A1 (ru) Лечение злокачественной опухоли гетероциклическими ингибиторами глутаминазы
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
IN2015KN00350A (ru)
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201990530A1 (ru) Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
JP2017508744A5 (ru)
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
EA202191992A1 (ru) Комбинированная терапия пролекарством don и ингибитором иммунных контрольных точек
EA202092767A1 (ru) Гетероконденсированные соединения пиридона и их применение в качестве ингибиторов идг
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EA202192800A1 (ru) Способы противоопухолевой терапии
MX2019005212A (es) Vacuna de adn dirigida a wt1 para terapia de combinacion.
MX2022002235A (es) Combinacion de urolitina con el tratamiento de inmunoterapia.